These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 317654)

  • 21. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
    Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunology and immunotherapy of human malignant melanoma.
    Bystryn JC
    Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL; Kasid A; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy using T cell defined tumor antigens for melanoma.
    Kawakami Y
    Microbiol Immunol; 1998; 42(12):801-13. PubMed ID: 10037214
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunophenotype of lymphocytes of patients with malignant melanoma and its dynamics during immunotherapy with interleukin-2].
    Kadagidze ZG; Iavorskiĭ VV; Baryshnikov AIu; Solov'eva EA; Savel'eva EV; Cheremushkin EA; Korotkova OV
    Vopr Onkol; 1991; 37(5):544-9. PubMed ID: 1767507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Passive immunotherapy of melanoma].
    Jotereau F; Labarriere N; Gervois N; Pandolfino MC; Dreno B
    Bull Cancer; 2003 Jul; 90(7):583-6. PubMed ID: 12957798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active-specific immunization against melanoma: is the problem at the receiving end?
    Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
    Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
    Gajewski TF
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen.
    Wang X; Luo W; Ferrone S
    Medicina (B Aires); 2000; 60 Suppl 2():48-50. PubMed ID: 11188931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine-based therapy and biochemotherapy for advanced melanoma.
    Atkins MB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
    Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
    Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor immunotherapy in melanoma: on the dawn of a new era?
    Wilcox R; Markovic SN
    Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunological aspects of malignant melanomas of the choroid].
    Le Hoang P
    Bull Soc Ophtalmol Fr; 1986 Nov; Spec No():143-51. PubMed ID: 3791545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.